Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Rifaximin eases bloating in patients with functional GI disorder

21 Mar 2024

Treatment with rifaximin appears effective in reducing bloating and distension, as well as the subjective severity of these symptoms, in patients with functional gastrointestinal disorder (FGID), results of a systematic review and meta-analysis have shown.

Rifaximin eases bloating in patients with functional GI disorder

21 Mar 2024

Bulevirtide works well against chronic hepatitis D, HIV/HBV/HDV coinfection

21 Mar 2024 bởi

Patients with hepatitis delta virus (HDV) show increased virologic and biochemical responses with longer bulevirtide (BLV) treatment for over 96 weeks, with no new safety concerns, as shown in a study presented at CROI 2024.

Bulevirtide works well against chronic hepatitis D, HIV/HBV/HDV coinfection

21 Mar 2024

Vitamin B6 best bet against antipsychotic-induced akathisia

20 Mar 2024 bởi

Mirtazapine, biperiden, and vitamin B6 are all beneficial in the treatment of antipsychotic-induced akathisia (AIA), with vitamin B6 having the best efficacy and tolerability profile, according to the results of a meta-analysis.

Vitamin B6 best bet against antipsychotic-induced akathisia

20 Mar 2024

COVID-19 rebound common following treatment with either VV116 or nirmatrelvir-ritonavir

20 Mar 2024

Among patients with mild-to-moderate COVID-19, viral rebound and symptom rebound occur frequently following a standard 5-day course of treatment with either VV116 or nirmatrelvir-ritonavir, as shown in a study from China.

COVID-19 rebound common following treatment with either VV116 or nirmatrelvir-ritonavir

20 Mar 2024

Original New Drug Application Approvals by US FDA (1-15 March 2024)

20 Mar 2024

New drug applications approved by US FDA as of 1-15 March 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 March 2024)

20 Mar 2024

Low-dose continuous kidney replacement therapy ups mortality in critically ill patients

19 Mar 2024

A lower delivered continuous kidney replacement therapy (CKRT) dose appears to be detrimental to critically ill patients with acute kidney injury (AKI), with a study showing that such an approach is associated with a higher 90-day mortality rate.

Low-dose continuous kidney replacement therapy ups mortality in critically ill patients

19 Mar 2024

Antidepressants improve cognition in people with late-life depression

19 Mar 2024

Use of antidepressant medication may lead to improvements in some areas of cognitive function, such as memory and learning, in individuals with late-life depression (LLD), a study has shown.

Antidepressants improve cognition in people with late-life depression

19 Mar 2024

Dupilumab mends skin barrier in children with AD, but with caveat

19 Mar 2024 bởi

Use of dupilumab results in normalization of stratum corneum (SC) lipids, which is responsible for skin barrier function, in children with atopic dermatitis (AD) within 1 to 2 months of treatment, according to a study presented at AAAAI 2024.

Dupilumab mends skin barrier in children with AD, but with caveat

19 Mar 2024

Frequent benzodiazepine intake not linked to long-term use, dose escalation

19 Mar 2024

Among adults receiving benzodiazepine receptor agonist (BZRA), a limited number are considered continuous users and a small portion have moved to a higher-than-recommended dose, reports a study.

Frequent benzodiazepine intake not linked to long-term use, dose escalation

19 Mar 2024

High viral suppression feasible with BIC/FTC/TAF + rifampicin in adults with HIV, TB

19 Mar 2024 bởi

Twice-daily treatment with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) resulted in high viral suppression among people with HIV and tuberculosis (TB) who were on rifampicin-based therapy, according to the INSIGHT* trial presented at CROI 2024.

High viral suppression feasible with BIC/FTC/TAF + rifampicin in adults with HIV, TB

19 Mar 2024

Tin tức & Cập nhật

Xem bài viết Dược

Xem

Chuyên ngành:

Rifaximin eases bloating in patients with functional GI disorder

Rifaximin eases bloating in patients with functional GI disorder

Bulevirtide works well against chronic hepatitis D, HIV/HBV/HDV coinfection

Bulevirtide works well against chronic hepatitis D, HIV/HBV/HDV coinfection

Vitamin B6 best bet against antipsychotic-induced akathisia

Vitamin B6 best bet against antipsychotic-induced akathisia

COVID-19 rebound common following treatment with either VV116 or nirmatrelvir-ritonavir

COVID-19 rebound common following treatment with either VV116 or nirmatrelvir-ritonavir

Original New Drug Application Approvals by US FDA (1-15 March 2024)

Original New Drug Application Approvals by US FDA (1-15 March 2024)

Low-dose continuous kidney replacement therapy ups mortality in critically ill patients

Low-dose continuous kidney replacement therapy ups mortality in critically ill patients

Antidepressants improve cognition in people with late-life depression

Antidepressants improve cognition in people with late-life depression

Dupilumab mends skin barrier in children with AD, but with caveat

Dupilumab mends skin barrier in children with AD, but with caveat

Frequent benzodiazepine intake not linked to long-term use, dose escalation

Frequent benzodiazepine intake not linked to long-term use, dose escalation

High viral suppression feasible with BIC/FTC/TAF + rifampicin in adults with HIV, TB

High viral suppression feasible with BIC/FTC/TAF + rifampicin in adults with HIV, TB